Company Overview
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Why Investors Should Care
Net profit has compounded at 10.0% per year over the last five years.
Revenue has grown at a 11.3% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.16.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.18B (+6.5% YoY); net profit $2.05M.
- Trailing 12 Months Year-on-year growth — revenue +14.9%, earnings -83.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.3%, profit CAGR 10.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 11.31% |
| 1 Year: | 14.90% |
Compounded Profit Growth
| 5 Years: | 10.04% |
| 1 Year: | -83.62% |
Stock Price Performance
| 1 Year: | +66.63% |
| 6 Months: | -9.46% |
| 3 Months: | +31.22% |
| 1 Month: | +21.47% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)64.12 · Neutral
P/E of 104.41 is above the sector median of 25.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 11.3% over 5 years.
- Profit CAGR of 10.0% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 104.4.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OMCL Omnicell, Inc. R2K | 45.94 | 104.41 | $2.09B | 0.00% | 0.34% | 1.63% | 11.31% | 10.04% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 202.52M | 217.41M | 228.81M | 229.69M | 199.62M | 213.70M | 251.84M | 272.74M | 296.40M | 318.83M | 331.39M | 348.06M | 290.63M | 298.97M | 298.66M | 246.15M | 276.79M | 282.42M | 269.67M | 290.56M | 310.63M | 309.88M |
| Gross Profit | 45.37M | 49.37M | 52.04M | 54.49M | 56.04M | 59.55M | 61.69M | 57.46M | 63.70M | 79.94M | 78.02M | 81.51M | 62.19M | 78.13M | 84.82M | 82.45M | 88.78M | 98.91M | 97.12M | 104.05M | 112.15M | 109.62M | 83.22M | 96.79M | 122.28M | 136.30M | 146.78M | 150.05M | 158.09M | 159.09M | 125.03M | 134.44M | 131.96M | 92.62M | 114.35M | 122.27M | 110.94M | 127.68M | 134.50M | 140.36M |
| Operating Income | 4.17M | 9.36M | 10.72M | 9.95M | 12.56M | 13.60M | 10.38M | 12.42M | 13.86M | 1.85M | -118.00K | 4.93M | -16.55M | -701.00K | 12.20M | 633.00K | 7.33M | 17.50M | 12.76M | 18.76M | 24.65M | 12.15M | -6.99M | 10.15M | 19.61M | 28.92M | 29.39M | 5.08M | 12.48M | 18.46M | -22.96M | 7.75M | 3.71M | -21.85M | 3.22M | 6.56M | -11.62M | 8.12M | 8.24M | 16.85M |
| Net Income | - | - | - | 6.19M | 7.79M | 7.30M | 6.32M | 8.75M | 8.04M | -378.00K | -1.16M | 1.98M | -10.34M | 1.88M | 7.75M | 2.72M | 6.59M | 13.63M | 3.28M | 15.98M | 19.98M | 11.31M | -4.30M | 8.80M | 14.13M | 20.42M | 29.32M | 8.21M | 9.07M | 16.77M | -15.00M | 3.45M | 5.55M | -15.68M | 3.73M | 8.63M | -7.02M | 5.64M | 5.46M | 11.36M |
| Diluted EPS | 0.10 | 0.17 | 0.21 | 0.17 | 0.21 | 0.20 | 0.17 | 0.24 | 0.22 | -0.01 | -0.03 | 0.05 | -0.28 | 0.05 | 0.20 | 0.07 | 0.16 | 0.33 | 0.08 | 0.37 | 0.46 | 0.26 | -0.10 | 0.20 | 0.30 | 0.43 | 0.61 | 0.17 | 0.20 | 0.37 | -0.33 | 0.08 | 0.12 | -0.34 | 0.08 | 0.19 | -0.15 | 0.12 | 0.12 | 0.25 |
| R&D Expense | 7.95M | 7.15M | 6.56M | 6.12M | 6.47M | 7.08M | 8.02M | 8.75M | 9.18M | 13.84M | 13.79M | 15.26M | 16.80M | 16.91M | 16.41M | 16.54M | 15.51M | 15.80M | 16.08M | 16.85M | 16.62M | 18.65M | 20.83M | 15.20M | 16.08M | 18.21M | 19.48M | 25.03M | 26.36M | 25.17M | 22.88M | 23.14M | 24.28M | 22.06M | 21.10M | 21.21M | 20.53M | 21.57M | 24.02M | 21.52M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 213.46M | 222.41M | 245.53M | 314.03M | 380.58M | 440.90M | 484.56M | 695.91M | 712.71M | 787.31M | 897.03M | 892.21M | 1.13B | 1.30B | 1.15B | 1.11B | 1.18B |
| Gross Profit | 105.22M | 117.92M | 135.78M | 170.59M | 203.40M | 233.86M | 247.93M | 317.08M | 318.64M | 372.33M | 436.91M | 413.29M | 554.65M | 588.99M | 496.84M | 471.00M | 503.44M |
| Operating Income | 669.00K | 9.53M | 16.22M | 27.13M | 35.30M | 49.58M | 48.63M | 21.41M | 11.14M | 44.39M | 78.35M | 35.53M | 89.51M | -2.32M | -34.87M | 337.00K | 5.16M |
| Net Income | 444.00K | 4.89M | 10.39M | 16.18M | 23.98M | 30.52M | 30.76M | 9.76M | 30.52M | 37.73M | 61.34M | 32.19M | 77.85M | 5.65M | -20.37M | 12.53M | 2.05M |
| Diluted EPS | 0.01 | 0.15 | 0.30 | 0.47 | 0.67 | 0.83 | 0.84 | 0.26 | 0.79 | 0.93 | 1.43 | 0.74 | 1.62 | 0.12 | -0.45 | 0.27 | 0.04 |
| R&D Expense | 17.57M | 21.01M | 22.04M | 23.73M | 29.11M | 27.80M | 35.16M | 57.80M | 66.02M | 64.84M | 68.64M | 70.16M | 75.72M | 104.97M | 97.11M | 90.41M | 88.67M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 343.22M | 363.85M | 441.82M | 492.50M | 560.21M | 578.75M | 935.10M | 1.02B | 1.08B | 1.24B | 1.82B | 2.14B | 2.21B | 2.23B | 2.12B | 1.97B |
| Total Equity | 233.56M | 242.30M | 265.21M | 282.91M | 307.55M | 349.00M | 390.10M | 420.46M | 458.84M | 554.34M | 679.62M | 845.25M | 967.50M | 1.15B | 1.13B | 1.19B | 1.24B | 1.23B |
| Cash & Equivalents | 120.44M | 169.23M | 175.63M | 191.76M | 62.31M | 104.53M | 125.89M | 82.22M | 54.49M | 32.42M | 67.19M | 127.21M | 485.93M | 349.05M | 330.36M | 467.97M | 369.20M | 196.52M |
| Long Term Debt | - | - | - | - | - | - | - | 0 | 245.73M | 194.92M | 135.42M | 50.00M | - | - | - | - | - | - |
| Total Liabilities | - | - | 78.01M | 80.94M | 134.27M | 143.50M | 170.12M | 176.36M | 503.50M | 462.02M | 401.62M | 395.56M | 857.00M | 995.81M | 1.08B | 1.04B | 877.65M | 742.91M |
| Current Liabilities | - | - | 58.16M | 60.63M | 83.08M | 92.40M | 112.33M | 124.63M | 180.91M | 205.21M | 204.58M | 237.00M | 276.42M | 876.16M | 428.45M | 367.79M | 595.68M | 476.61M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | 39.48M | 55.26M | 65.16M | 38.49M | 49.90M | 24.83M | 103.97M | 145.01M | 185.87M | 231.81M | 77.78M | 181.09M | 187.72M | 127.30M |
| Investing Cash Flow | - | - | - | -168.71M | -20.45M | -43.33M | -45.60M | -341.32M | -34.99M | -54.37M | -61.66M | -279.87M | -412.50M | -58.67M | -55.02M | -52.79M | -60.36M |
| Financing Cash Flow | - | - | - | -232.00K | 7.37M | -206.00K | -36.56M | 263.75M | -9.88M | -13.60M | -23.48M | 456.27M | 47.36M | -20.95M | 23.42M | -235.58M | -218.32M |
| Capital Expenditure | -3.65M | -6.89M | -8.69M | -15.12M | -12.34M | -11.92M | -7.54M | -13.45M | -15.34M | -23.70M | -15.89M | -22.84M | -28.97M | -47.54M | -41.47M | -36.46M | -40.41M |
| Free Cash Flow | - | - | - | 24.36M | 42.93M | 53.24M | 30.94M | 36.45M | 9.49M | 80.27M | 129.11M | 163.03M | 202.84M | 30.25M | 139.62M | 151.26M | 86.89M |
| Share Buybacks | - | 0 | 12.57M | 12.36M | 20.96M | 24.09M | 50.02M | 0 | 0 | 0 | 0 | 53.03M | 0 | 52.21M | 0 | 0 | 77.60M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 49.3% | 53.0% | 55.3% | 54.3% | 53.4% | 53.0% | 51.2% | 45.6% | 44.7% | 47.3% | 48.7% | 46.3% | 49.0% | 45.4% | 43.3% | 42.3% | 42.5% |
| Operating Margin % | 0.3% | 4.3% | 6.6% | 8.6% | 9.3% | 11.2% | 10.0% | 3.1% | 1.6% | 5.6% | 8.7% | 4.0% | 7.9% | -0.2% | -3.0% | 0.0% | 0.4% |
| Net Margin % | 0.2% | 2.2% | 4.2% | 5.2% | 6.3% | 6.9% | 6.3% | 1.4% | 4.3% | 4.8% | 6.8% | 3.6% | 6.9% | 0.4% | -1.8% | 1.1% | 0.2% |
| ROE % | 0.2% | 1.8% | 3.7% | 5.3% | 6.9% | 7.8% | 7.3% | 2.1% | 5.5% | 5.6% | 7.3% | 3.3% | 6.8% | 0.5% | -1.7% | 1.0% | 0.2% |
| ROCE % | - | 3.3% | 5.3% | 7.6% | 8.8% | 11.1% | 10.7% | 2.8% | 1.4% | 5.1% | 7.8% | 2.3% | 7.1% | -0.1% | -1.9% | 0.0% | 0.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.85% | 7.21M | $331.68M |
| 2 | Vanguard Portfolio Management LLC | 7.07% | 3.21M | $147.94M |
| 3 | Wellington Management Group, LLP | 5.95% | 2.71M | $124.58M |
| 4 | Dimensional Fund Advisors LP | 5.39% | 2.45M | $112.77M |
| 5 | Millennium Management Llc | 5.03% | 2.29M | $105.32M |
| 6 | State Street Corporation | 4.29% | 1.95M | $89.76M |
| 7 | Vanguard Capital Management LLC | 4.25% | 1.93M | $89.03M |
| 8 | Lazard Asset Management LLC | 3.23% | 1.47M | $67.65M |
| 9 | Sumitomo Mitsui Trust Group, Inc. | 3.10% | 1.41M | $64.93M |
| 10 | Nomura Asset Management International Inc | 2.60% | 1.18M | $54.47M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OMCL
Should You Continue to Hold OMCL Stock in Your Portfolio Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQQ0xhMGpoTHhGbkNlZWVzYWVvd3hjVlc2dDlSR2cwSkQ3ak1Sb3RwaVBkX1JrV0xZQzlvdHluS3kxbms5RmlhN0FERmU0TU4tdjgyRWNMMGJvMHEwU2NUejBMejRyWG90ck9xbjVpTGdjUDhBeWZaSkVTQktFVUZPSVpnN3NkSzVIb1VtQV…
Earnings day ahead: Omnicell to unveil Q2 2026 results on July 30 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPVmJ2Skstek9oZWJtM0c1UlRWWElrSldqZUhiTjl4andZQktvS1BxNE1XblRlNTI0MUdoUVNRSkhta2wyUk1QZU9XS08wcVE4QlYxclNXWWxlWmh4NGNMVjZXU1htTXI1UnVEbG9BSDR1dFF2d3h4V1ZVQ3lRLWY2QlFmZ1RUOU1qLU5fU1…
Does Omnicell’s ESOP Share Registration and Leadership Shift Reframe Its Capital Allocation Story (OMCL)? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNNEtzR05pMThZMFByMzFUdmpmREw2Z0RPWjBhR2ZKekJBRFViSFpiZ2RLdEZZa0lad3J0WWtWbjR4M1BDUTFsVkN1MjBlcl80RFFoX19JRG1GdHNIaExJRVRUakdSOFplOTA1dWJkVVkyd21Lb00zZld4bnktdndHVEViQ0FXMVpyRXl4WU…
OMCL Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1qaVVUb2pnMVR2VVpBSVEweGJPNDNwc19rWDA1eXF4cGNLdzFBcVMxa0xfclJSSUw2dmUzZXBtSEZSV2VnQkE4b2VzdlJwNXVlLXRVZFg5MjVEdW5Ua3ZVQUtXenNYZm9vQjZLTnZfR1hVMWhHZ2hTNDFn?oc=5" target="_blank">OMC…
1 Profitable Stock with Exciting Potential and 2 That Underwhelm - StockStory
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOT0hHbVUwVVMyT2swd0FwbW95RmUwclc0WmlseWJLWmFFTVlqZVJUWFNENElTblNpRVNBa2Z4VzNYc0pTYldFbHU3VUR6cVpHT2JGZFpmaFk2SUNfSVhRa2lZU2VHYXdlOWpqNExycUF4Z1psQWxTbHBGbENvVExOeDc5SEs0VnFpZXRtUn…
The Bull Case For Omnicell (OMCL) Could Change Following New President And ESOP Share Offering - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNWktOOFdOZmQtemVRaEZQVHlNY2VpZ0hnRkFDeE5OZHIzUmoyUlNfYTNUSTVBSHNSWW05enQtY2h6UklIT0g4dC1wU1ZDMXZRS3hqYi10WWJ5NDRGeWoteHVBMTJIaG1QNFdZeVhGVjZ2V1ZjcW9Id2x0emNoYmFRQTNVaE9VMGFKd3AzVk…
OMCL — Frequently Asked Questions
What is the current share price of Omnicell, Inc. (OMCL)?
As of 2026-07-14 21:23 PDT, Omnicell, Inc. (OMCL) trades at $45.94 on NasdaqGS. Its 52-week range is $26.88 to $51.39.
What is the market capitalisation of OMCL?
Omnicell, Inc. (OMCL) has a market capitalisation of $2.09B on NasdaqGS.
What is the P/E ratio of OMCL?
OMCL trades at a trailing price-to-earnings (P/E) ratio of 104.41. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.37.
What is the return on equity (ROE) of OMCL?
OMCL has a return on equity (ROE) of 1.63%. Its return on capital employed (ROCE) is 0.34%.
Is OMCL a good stock to buy?
This page provides a data-driven analysis of Omnicell, Inc. (OMCL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.